Thermo Fisher Scientific Inc. (NYSE:TMO) Bernstein 39th Annual Strategic Decisions Conference Call May 31, 2023 11:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Good morning, everyone. Let's go ahead and get started. My name is Eve Burstein, and I'm a new analyst at Bernstein. No relation, even though the names sound similar. Pre-launch, we'll be launching on US life science tools and ...

Thermo Fisher Scientific Inc. (NYSE:TMO) BofA Securities 2023 Healthcare Conference Call May 10, 2023 11:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Derik Bruin - Bank of America Securities Operator Abrupt start Â…2023 Healthcare Conference coming to live from the Encore in Las Vegas. Kicking off our session today is Thermo Fisher Scientific. And with us is Marc Casper, Chairman, President and CEO. I'm Derik De Bruin, the Senior Li ...

财务数据和关键指标变化 - 本季度营收107.1亿美元，调整后运营收入23.3亿美元，调整后每股收益5.03美元 [14] - 核心有机收入增长6%，调整后每股收益比之前2023年预期高出0.02美元，GAAP每股收益为3.32美元，报告收入同比下降9%，包括8%的有机收入下降、1%的收购贡献和2%的外汇逆风 [45][46] - 调整后运营利润率为21.8%，比去年第一季度低740个基点，调整后毛利率为40.3%，比去年第一季度低720个基点，调整后SG&A占收入的15.3%，总研发费用为3.5亿美元，占制造收入的6.9%，净利息费用为1.54亿美元，调整后税率为10%，平均稀释股份为3.88亿股 [49][50][51][52] - 运营现金流为7.3亿美元，自由现金流为2.8亿美元，资本支出31亿美元用于收购The Binding Site和回报股东（回购和分红），本季度末现金35亿美元，总债务353亿美元，杠杆率为3.2倍（总债务与调整后EBITDA之比）和2.9倍（净债务基础），调整后ROIC为12.2% [53][54] 各条业务线数据和关键指标变化 Life Science Solutions - 本季度报告收入下降38%，有机收入比去年同期下降37%，调整后运营收入下降62%，调整后运营利润率为32%，比去年同期下降19个百分点 [56][57] Analytical Instruments - 报告收入增长14%，有机增长17%，调整后运营收入增长40%，调整后运营利润率为24.4%，比去年同期上升460个基点 [58] Specialty Diagnostics - 报告收入下降25%，有机收入比去年同期下降28%，调整后运营收入下降21%，调整后运营利润率为25.3%，比去年同期高140个基点 [59][60] Laboratory Products and Biopharma Services - 报告收入增长6%，有机增长7%，调整后运营收入增长28%，调整后运营利润率为13.8%，比去年同期高240个基点 [61][62] 各个市场数据和关键指标变化 地域 - 北美下降高个位数，欧洲下降低双位数，亚太地区增长低个位数（中国略有下降），世界其他地区下降高个位数 [48] 公司战略和发展方向和行业竞争 增长战略 - 包括开发高影响力创新产品、利用规模和新兴市场高增长、为客户提供独特价值主张三个支柱 [20] - 创新方面，本季度在各业务推出多个高影响力新产品，如在元素分析、基因科学、生物科学和临床诊断业务等领域 [21][22][23] - 利用规模和新兴市场方面，在中国苏州开设新设施 [25][26] - 增强客户价值主张方面，与客户深入合作，如与加州大学旧金山分校建立战略合作伙伴关系，在细胞疗法开发等方面提供解决方案 [27][28][29] 资本部署 - 年初收购The Binding Site，整合顺利，业务表现良好，本季度回购30亿美元股票，股息增加17% [35][36][37] 管理层对经营环境和未来前景的评论 经营环境 - 宏观环境更具挑战性，但公司增长战略和PPI业务系统使其能够有效应对，包括管理疫情相关收入流失和推动核心有机收入增长及份额提升 [44] 未来前景 - 维持2023年全年收入453亿美元和调整后每股收益23.70美元的指导，预计下半年收入和调整后每股收益权重略高，核心有机增长预计第二季度为中个位数，全年包括7%的核心有机收入增长 [63][72][73] 其他重要信息 - 公司在《财富》最具创新力公司榜单中排名第22位 [24] - 推进环境、社会和治理优先事项，包括到2026年为美国所有现有站点提供100%可再生能源，加速实现2050年净零碳排放承诺 [37][38] 问答环节所有的提问和回答 问题：lab products, biopharma services相关，PPD本季度增长情况、前景假设以及奖励趋势 - 回答：PPD年初增长强劲，增长率持续在十几岁中期，业务受益于收入协同效应，有强大的积压订单和授权水平，渠道业务表现良好，持续赢得客户 [78][80] 问题：公司当前的可见性水平，不同客户群体之间是否有差异，PPD对可见性的影响 - 回答：公司整体有良好增长，部分业务表现优于预期，如分析仪器业务对Q3有更多可见性，生物生产业务上半年面临更多逆风，但这是暂时现象，长期前景良好，不同客户群体可见性与客户生产相关，总体合理 [89][90][91][92][93] 问题：Analytical Instrument增长预期以及是否有增长更快的终端市场 - 回答：仪器业务受益于创新产品的采用，预计Q2有良好增长，Q3增长将比预期更好，增长优势广泛，如半导体、电池技术相关业务表现良好 [97][98][99] 问题：对指导的信心以及是否有进一步调整的空间 - 回答：公司管理原则是提供差异化表现并长期强化公司，基于Q1结果和对全年的假设对指导有信心，如果假设变化会适当调整指导 [102][103][104][105][106] 问题：生物生产和库存相关动态，公司业务与其他公司的差异 - 回答：2023年疫苗和疗法收入主要在制药服务业务，COVID疫苗相关进展符合预期，生物生产方面，客户因产品交付时间改善而调整订单，公司产品性质决定客户不会过度库存，预计上半年较软下半年回升 [109][110][111][112][113][114][115][116][117] 问题：生物制药业务各组成部分（消耗品、CDMO和PPD）的增长预期 - 回答：制药和生物技术业务本季度实现中个位数增长，受疫苗和疗法收入流失影响，预计今年增长将比去年更温和，Q1与预期相似，生物生产较软，不同业务细节不按客户方管理，生物生产约占收入10% [123][124][125][126][127] 问题：仪器业务如何逆势增长以及相关优势 - 回答：团队执行良好，应对供应链问题，通过突破创新战略赢得业务，预计增长下半年将适度放缓但Q3好于预期 [129][130][131] 问题：中国市场趋势以及对PPD增长的归因 - 回答：中国市场Q1表现符合预期，业务略有下降但核心增长高个位数，预计全年将继续加强，PPD团队执行良好，因公司优势有高授权水平，预计明年有2.5亿美元收入协同效应 [136][137][142][143] 问题：生物制药终端市场指导是否改变以及公司对早期生物技术的风险敞口 - 回答：整体指导变化不大，仪器和专业诊断稍强，生物生产稍软，早期生物技术是重要客户群体，公司服务良好，科学和热情非凡，公司在制药和生物技术领域有强大地位 [148][149][150][151][152] 问题：仪器和设备服务业务（Unity）的表现 - 回答：该业务稳定增长，因仪器数量增长带来的保修到期驱动增量需求，电子显微镜业务客户对服务需求大 [160][161][162] 问题：资本部署前景以及对通胀削减法案的看法 - 回答：资本部署环境良好，因利率较高竞争减少，公司将继续积极寻找机会，对通胀削减法案，客户正在研究其影响，目前未看到重大变化 [170][171][169]

Thermo Fisher Scientific Inc. (NYSE:TMO) Cowen 43rd Annual Healthcare Conference March 6, 2023 9:10 AM ET Company Participants Marc N. Casper – Chairman, President and CEO Conference Call Participants Dan Brennan – Cowen Dan Brennan Pleased to be joining with me here on stage Marc Casper, Chairman, President, and CEO of Thermo Fisher. I am going to first say thank you Marc for coming. Appreciate it. And Eileen Pattinson here in the front row, so I thought Marc, maybe you can just kick it off with some openi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 04-2209186 (State of incorporation) (I.R.S. Employer Identification No.) 168 Thir ...

GAAP/Non-GAAP Reconciliation and Financial Package February 1, 2023 Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We also report Core organic revenue growth, which is reported revenue growth ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Q4 2022 Earnings Conference Call February 1, 2023 8:30 AM ET Company Participants Rafael Tejada – Vice President-Investor Relations Marc Casper – Chairman, President and Chief Executive Officer Stephen Williamson – Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan – Nephron Research Patrick Donnelly – Citi Rachel Vatnsdal – J.P. Morgan Derik de Bruin – Bank of America Dan Brennan – Cowen Vijay Kumar – Evercore ISI Dan Arias – ...

Thermo Fisher Scientific Inc. (NYSE:TMO) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JP Morgan Operator Rachel Vatnsdal Good morning, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team from JP Morgan. I'm joined today by Marc Casper, CEO of Thermo Fisher Scientific. So today will be a 40-minute presentation. We'll sta ...

41st Annual J.P. Morgan Healthcare Conference Marc N. Casper Chairman, President and Chief Executive Officer January 10th, 2023 The world leader in serving science 1 Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentations about the company's future expectations, plans and prospects constitute forwardlooking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements about future revenue, financ ...

40th Annual J.P. Morgan Option 2 Healthcare Conference Marc N. Casper Chairman, President and Chief Executive Officer January 11, 2022 The world leader in serving science Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentation about the company's future expectations, plans and prospects constitute forwardlooking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements about future revenue, fi ...